EP1487965A4 - Compositions minicellulaires et methodes associees - Google Patents
Compositions minicellulaires et methodes associeesInfo
- Publication number
- EP1487965A4 EP1487965A4 EP02747872A EP02747872A EP1487965A4 EP 1487965 A4 EP1487965 A4 EP 1487965A4 EP 02747872 A EP02747872 A EP 02747872A EP 02747872 A EP02747872 A EP 02747872A EP 1487965 A4 EP1487965 A4 EP 1487965A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- methods
- minicell compositions
- minicell
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/5432—Liposomes or microcapsules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10008869.9A EP2272946B9 (fr) | 2002-02-25 | 2002-05-28 | Compositions et méthodes de minicellules |
EP20110000796 EP2390308A1 (fr) | 2002-02-25 | 2002-05-28 | Compositions de minicellules et procédés |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US154951 | 1988-02-10 | ||
US35984302P | 2002-02-25 | 2002-02-25 | |
US359843P | 2002-02-25 | ||
US10/154,951 US20030194798A1 (en) | 2001-05-24 | 2002-05-24 | Minicell compositions and methods |
PCT/US2002/016877 WO2003072014A2 (fr) | 2002-02-25 | 2002-05-28 | Compositions minicellulaires et methodes associees |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10008869.9A Division EP2272946B9 (fr) | 2002-02-25 | 2002-05-28 | Compositions et méthodes de minicellules |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1487965A2 EP1487965A2 (fr) | 2004-12-22 |
EP1487965A4 true EP1487965A4 (fr) | 2006-11-15 |
Family
ID=27767433
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02747872A Withdrawn EP1487965A4 (fr) | 2002-02-25 | 2002-05-28 | Compositions minicellulaires et methodes associees |
EP20110000796 Withdrawn EP2390308A1 (fr) | 2002-02-25 | 2002-05-28 | Compositions de minicellules et procédés |
EP10008869.9A Revoked EP2272946B9 (fr) | 2002-02-25 | 2002-05-28 | Compositions et méthodes de minicellules |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20110000796 Withdrawn EP2390308A1 (fr) | 2002-02-25 | 2002-05-28 | Compositions de minicellules et procédés |
EP10008869.9A Revoked EP2272946B9 (fr) | 2002-02-25 | 2002-05-28 | Compositions et méthodes de minicellules |
Country Status (6)
Country | Link |
---|---|
EP (3) | EP1487965A4 (fr) |
AU (1) | AU2002318168B2 (fr) |
CA (1) | CA2517027A1 (fr) |
ES (1) | ES2541351T3 (fr) |
HK (1) | HK1153229A1 (fr) |
WO (1) | WO2003072014A2 (fr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030194798A1 (en) | 2001-05-24 | 2003-10-16 | Surber Mark W. | Minicell compositions and methods |
US7396822B2 (en) | 2001-05-24 | 2008-07-08 | Vaxiion Therapeutics, Inc. | Immunogenic minicells and methods of use |
JP4458846B2 (ja) * | 2001-10-15 | 2010-04-28 | エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド | invitroおよびinvivoにおけるDNA導入および遺伝子療法のためのベクターとしての完全なミニ細胞 |
US7611885B2 (en) | 2003-06-24 | 2009-11-03 | Engeneic Molecular Delivery Pty, Ltd. | Pharmaceutically compatible method for purifying intact bacterial minicells |
ATE501735T1 (de) | 2003-12-09 | 2011-04-15 | Engeneic Molecular Delivery Pty Ltd | Gezielte genabgabe an nicht-phagozytische säugetierzellen über bakteriell erhaltene intakte minizellen |
US8772013B2 (en) | 2004-02-02 | 2014-07-08 | Engeneic Molecular Delivery Pty Ltd | Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells |
SG169373A1 (en) * | 2004-02-02 | 2011-03-30 | Engeneic Molecular Delivery Pty Ltd | Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells |
JP4114075B2 (ja) * | 2004-02-16 | 2008-07-09 | ヒューマン・メタボローム・テクノロジーズ株式会社 | 遺伝子産物の機能同定方法及び結合物質同定方法 |
US8055347B2 (en) | 2005-08-19 | 2011-11-08 | Brainsgate Ltd. | Stimulation for treating brain events and other conditions |
US8010189B2 (en) | 2004-02-20 | 2011-08-30 | Brainsgate Ltd. | SPG stimulation for treating complications of subarachnoid hemorrhage |
US9233245B2 (en) | 2004-02-20 | 2016-01-12 | Brainsgate Ltd. | SPG stimulation |
WO2006055024A2 (fr) * | 2004-04-05 | 2006-05-26 | Vaxiion Therapeutics, Inc. | Minicellules employees comme vaccins |
JP4965447B2 (ja) | 2004-08-26 | 2012-07-04 | エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド | 細菌由来のインタクトなミニセルを介した哺乳動物細胞への機能性核酸の送達 |
US9878043B2 (en) | 2006-06-23 | 2018-01-30 | Engeneic Molecular Delivery Pty Ltd | Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells |
EP2675474B1 (fr) | 2011-02-15 | 2019-01-16 | Vaxiion Therapeutics, LLC | Compositions thérapeutiques et procédés d'administration ciblée de molécules bioactives par des minicellules bactériennes basée sur des molécules de ciblage contenant un fragment fc et des anticorps |
US20140342932A1 (en) * | 2011-09-23 | 2014-11-20 | Merck Sharp & Dohme Corp. | Functional cell surface display of ligands for the insulin and/or insulin growth factor 1 receptor and applications thereof |
EP2878335B1 (fr) | 2013-11-10 | 2018-01-03 | Brainsgate Ltd. | Implant et système d'implantation pour stimulateur neural |
RU2577138C1 (ru) * | 2014-11-25 | 2016-03-10 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Способ получения рекомбинантного белка sav-rgd |
EP3093043B1 (fr) | 2015-05-13 | 2018-11-14 | Brainsgate Ltd. | Implant et système de distribution pour stimulateur neural |
US11649265B2 (en) | 2017-04-28 | 2023-05-16 | Agrospheres, Inc. | Compositions and methods for the encapsulation and scalable delivery of agrochemicals |
CA3073449A1 (fr) | 2017-09-25 | 2019-03-28 | Agrospheres, Inc. | Compositions et procedes de production et d'administration evolutive de produits biologiques |
WO2020141495A1 (fr) * | 2019-01-04 | 2020-07-09 | Engeneic Molecular Delivery Pty Ltd | Antigènes glycolipidiques encapsulés pour le traitement de maladies néoplasiques |
CN110669811A (zh) * | 2019-10-21 | 2020-01-10 | 天津大学 | 一种提高表面活性素产量的方法 |
JP2023517051A (ja) * | 2020-03-06 | 2023-04-21 | エンドリティクス テクノロジー インコーポレイテッド | 細胞内細菌を治療するための組成物及び方法 |
CN116087504B (zh) * | 2023-02-24 | 2023-08-15 | 上海碧云天生物技术有限公司 | 免疫磁珠保护液、其制备方法及应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003033519A2 (fr) * | 2001-10-15 | 2003-04-24 | Engeneic Gene Therapy Pty Limited | Mini-cellules entieres utilisees en tant que vecteurs pour le transfert d'adn et la therapie genique in vitro et in vivo |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4132769A (en) | 1974-10-30 | 1979-01-02 | Osther Kurt B | Cancer antigen, cancer therapy, and cancer diagnosis |
US4237224A (en) | 1974-11-04 | 1980-12-02 | Board Of Trustees Of The Leland Stanford Jr. University | Process for producing biologically functional molecular chimeras |
US5212071A (en) | 1988-04-01 | 1993-05-18 | The Johns Hopkins University | Nucleic acids encoding a human C3b/C4b receptor (CR1) |
US4190495A (en) | 1976-09-27 | 1980-02-26 | Research Corporation | Modified microorganisms and method of preparing and using same |
US4311797A (en) | 1979-09-18 | 1982-01-19 | University Of Saskatchewan | Anucleated live E. coli vaccine |
US4497796A (en) | 1980-03-26 | 1985-02-05 | The Regents Of The University Of California | Gene transfer in intact mammals |
US4895724A (en) | 1985-06-07 | 1990-01-23 | Pfizer Inc. | Chitosan compositions for controlled and prolonged release of macromolecules |
US4839293A (en) | 1986-02-24 | 1989-06-13 | The Trustees Of Columbia University In The City Of New York | DNA encoding streptavidin, streptavidin produced therefrom, fused polypeptides which include amino acid sequences present in streptavidin and uses thereof |
US5869620A (en) | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4921790A (en) | 1987-04-24 | 1990-05-01 | Research Corporation | Tumor specific assay for CA125 ovarian cancer antigen |
US5654176A (en) | 1987-05-28 | 1997-08-05 | Amrad Corporation Limited | Fusion proteins containing glutathione-s-transferase |
US5053489A (en) | 1988-01-29 | 1991-10-01 | Dana-Farber Cancer Institute, Inc. | Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen |
US4963484A (en) | 1988-01-29 | 1990-10-16 | Dana-Farber Cancer Institute, Inc. | Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen |
US4914021A (en) | 1988-03-04 | 1990-04-03 | New England Deaconess Hospital Corporation | Carcinoma orosomucoid-related antigen, a monoclonal antibody thereto, and their uses |
US6307030B1 (en) | 1988-04-15 | 2001-10-23 | The University Of North Carolina At Chapel Hill | Androgen receptor proteins, recombinant DNA molecules coding for such, and use of such compositions |
WO1990012091A1 (fr) | 1989-04-07 | 1990-10-18 | Cancerforskningsfondet Af 1989 | Recepteur de l'activateur du plasminogene du type urokinase |
US6261800B1 (en) | 1989-05-05 | 2001-07-17 | Genentech, Inc. | Luteinizing hormone/choriogonadotropin (LH/CG) receptor |
US5260432A (en) | 1989-06-22 | 1993-11-09 | Sloan-Kettering Institute For Cancer Research | Human gamma retinoic acid receptor DNA |
US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
US5674980A (en) | 1989-12-21 | 1997-10-07 | Biogen Inc | Fusion protein comprising tat-derived transport moiety |
US5773024A (en) | 1989-12-22 | 1998-06-30 | Imarx Pharmaceutical Corp. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
CA2076386C (fr) | 1990-02-26 | 2003-04-22 | David S. Hogness | Identification et expression d'une sequence d'adn d'insecte ayant les caracteristiques des recepteurs steroides d'insecte |
DE69131393T2 (de) | 1990-09-10 | 1999-11-04 | Takeda Chemical Industries Ltd | Menschlicher Rezeptor für luteinisierendes Hormon und Choriongonadotropin |
US5314695A (en) | 1990-11-13 | 1994-05-24 | Corvas International, Inc. | Tissue factor based prothrombin time reagent |
US5840867A (en) | 1991-02-21 | 1998-11-24 | Gilead Sciences, Inc. | Aptamer analogs specific for biomolecules |
JP3050424B2 (ja) | 1991-07-12 | 2000-06-12 | 塩野義製薬株式会社 | ヒトエンドセリンリセプター |
US6025165A (en) | 1991-11-25 | 2000-02-15 | Enzon, Inc. | Methods for producing multivalent antigen-binding proteins |
GB2265375A (en) | 1992-03-16 | 1993-09-29 | Merck & Co Inc | Human nuerokinin-3 receptor |
US6225080B1 (en) | 1992-03-23 | 2001-05-01 | George R. Uhl | Mu-subtype opioid receptor |
US5837521A (en) | 1993-04-08 | 1998-11-17 | State Of Oregon | Nucleic acids encoding the γ-MSH receptor MC3-R |
US5532347A (en) | 1992-04-10 | 1996-07-02 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non-Profit Organization | DNA encoding α melanocyte stimulating hormone receptor |
US6313279B1 (en) | 1992-05-01 | 2001-11-06 | Eli Lilly And Company | Human glutamate receptor and related DNA compounds |
FR2692592B1 (fr) | 1992-06-19 | 1995-03-31 | Pasteur Merieux Serums Vacc | Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant. |
ATE242321T1 (de) | 1992-08-13 | 2003-06-15 | Univ California | Delta opioidrezeptor-gene |
US6300087B1 (en) | 1992-11-03 | 2001-10-09 | Synaptic Pharmaceutical Corporation | DNA encoding a human serotonin receptor (5-HT4B) and uses thereof |
EP0672129A4 (fr) | 1992-11-20 | 1997-06-11 | Univ New Jersey Med | Transfert de genes specifique a un type cellulaire a l'aide de vecteurs retroviraux contenant des proteines de fusion enveloppe-anticorps. |
DE69432926T2 (de) | 1993-02-05 | 2004-05-13 | Epigen, Inc., Wellesley | Humanes carcinoma-antigen (hca), hca antikörper, hca immunoassays, aufzeichnungsmethoden und therapy |
US6258556B1 (en) | 1993-02-26 | 2001-07-10 | The United States Of America As Represented By The Department Of Health And Human Services | cDNA and genomic clones encoding human μ opiate receptor and the purified gene product |
US6235496B1 (en) | 1993-03-08 | 2001-05-22 | Advanced Research & Technology Institute | Nucleic acid encoding mammalian mu opioid receptor |
ES2182843T3 (es) | 1993-04-20 | 2003-03-16 | Merck & Co Inc | Subunidades de receptor humano de n-metil-d-aspartato, acidos nucleicos que codifican las mismas y su uso. |
US5716789A (en) | 1993-07-26 | 1998-02-10 | Cor Therapeutics, Inc. | Method to determine ligands, agonist and antagonist of C140 receptor |
US6291206B1 (en) | 1993-09-17 | 2001-09-18 | Genetics Institute, Inc. | BMP receptor proteins |
NZ273015A (en) | 1993-09-20 | 1997-09-22 | Ciba Geigy Ag | Human metabotropic glutamate receptor proteins, production, dna code, fusion proteins, antibodies and method of detecting glutamate agonist |
AU705998B2 (en) | 1993-11-08 | 1999-06-03 | Connaught Laboratories Limited | Haemophilus transferrin receptor genes |
US6248554B1 (en) | 1993-11-24 | 2001-06-19 | The Procter & Gamble Company | DNA sequence coding for a BMP receptor |
US6225531B1 (en) | 1994-06-17 | 2001-05-01 | Kirin Beer Kabushiki Kaisha | Glucan elicitor receptor, DNA molecule coding therefor, fungus-resistant plants transformed with the DNA molecule and method for creating the plants |
GB9416536D0 (en) | 1994-08-16 | 1994-10-12 | Karobio Ab | Orphan receptor |
JP3949715B2 (ja) | 1994-09-05 | 2007-07-25 | アムラド・オペレイションズ・プロプライエタリー・リミテッド | 新規ヘモポイエチン受容体 |
US6306622B1 (en) | 1994-11-04 | 2001-10-23 | The Procter & Gamble Co. | cDNA encoding a BMP type II receptor |
US6245893B1 (en) | 1994-12-17 | 2001-06-12 | Smithkline Beecham P.L.C. | Receptor that binds anti-convulsant compounds |
EP0812353A2 (fr) | 1995-01-26 | 1997-12-17 | Merck Frosst Canada Inc. | Recepteur dp de prostaglandine |
US6111079A (en) | 1995-06-05 | 2000-08-29 | Bionebraska, Inc. | Lead binding polypeptides and nucleotides coding therefore |
US6025191A (en) | 1995-06-07 | 2000-02-15 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules which encode a melanoma specific antigen and uses thereof |
US6291207B1 (en) | 1995-07-28 | 2001-09-18 | Northwestern University | Herpes virus entry receptor protein |
US6290970B1 (en) | 1995-10-11 | 2001-09-18 | Aventis Pasteur Limited | Transferrin receptor protein of Moraxella |
US6017721A (en) | 1995-10-18 | 2000-01-25 | The United States Of America As Represented By The Department Of Health And Human Services | Chromatographic method and device for preparing blood serum for compatibility testing |
US6048539A (en) | 1995-11-02 | 2000-04-11 | Connaught Laboratories Limited | Lactoferrin receptor protein |
US6265184B1 (en) | 1995-12-20 | 2001-07-24 | Icos Corporation | Polynucleotides encoding chemokine receptor 88C |
US6268214B1 (en) | 1996-04-04 | 2001-07-31 | Roche Diagnostics Gmbh | Vectors encoding a modified low affinity nerve growth factor receptor |
US5965392A (en) | 1996-04-08 | 1999-10-12 | Bayer Corporation | Neuropeptide Y receptor Y5 and nucleic acid sequences |
US6271347B1 (en) | 1996-04-26 | 2001-08-07 | Merck & Co., Inc. | Eosinophil eotaxin receptor |
US6258944B1 (en) | 1996-05-06 | 2001-07-10 | Merck & Co., Inc. | OB receptor isoforms and nucleic acids encoding them |
WO1998011221A2 (fr) | 1996-09-13 | 1998-03-19 | Dana-Farber Cancer Institute | Car, un nouveau recepteur du virus de coxsackie et d'adenovirus |
CA2275465A1 (fr) | 1996-12-27 | 1998-07-09 | Merck & Co., Inc. | Recepteur de galanine galr2 et nucleotides codant celui-ci |
DE69834027D1 (de) | 1997-01-14 | 2006-05-18 | Human Genome Sciences Inc | Tumor-nekrose-faktor rezeptor 5 |
US6017735A (en) | 1997-01-23 | 2000-01-25 | Marie Curie Cancer Care | Materials and methods for intracellular transport and their uses |
US6242251B1 (en) | 1997-03-18 | 2001-06-05 | Eli Lilly And Company | Rhesus neuropeptide Y5 receptor |
JP3885177B2 (ja) | 1997-03-26 | 2007-02-21 | 大塚製薬株式会社 | ヒト遺伝子 |
US6086900A (en) | 1997-03-26 | 2000-07-11 | Board Of Regents, The University Of Texas Systems | Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes |
US5951951A (en) | 1997-04-30 | 1999-09-14 | Medtronic, Inc. | Platelet function evaluation technique for citrated whole blood |
GB9710699D0 (en) | 1997-05-24 | 1997-07-16 | Danbiosyst Uk | Gastro-retentive controlled release system |
WO1999009140A1 (fr) | 1997-08-20 | 1999-02-25 | The Regents Of The University Of California | Sequences nucleotidiques codant pour le recepteur de la capsicine, polypeptides lies au recepteur de la capsicine et leur utilisation |
US6222015B1 (en) | 1997-09-08 | 2001-04-24 | Merck & Co., Inc. | Estrogen receptor |
DE69837811D1 (de) | 1997-11-11 | 2007-07-05 | Ono Pharmaceutical Co | Menschlicher lysophosphatidsäure rezeptor und dessen verwendung |
US6210967B1 (en) | 1997-12-10 | 2001-04-03 | Synaptic Pharmaceutical Corporation | DNA encoding a mammalian LPA receptor and uses thereof |
JP4855577B2 (ja) | 1998-06-01 | 2012-01-18 | アジェンシス,インコーポレイテッド | ヒト癌で発現される新規蛇行性膜貫通抗原およびその使用 |
US6248520B1 (en) | 1998-07-06 | 2001-06-19 | The Rockefeller University | Nucleic acid molecules encoding nuclear hormone receptor coactivators and uses thereof |
US6221613B1 (en) | 1998-12-31 | 2001-04-24 | Synaptic Pharmaceutical Corporation | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof |
US6221660B1 (en) | 1999-02-22 | 2001-04-24 | Synaptic Pharmaceutical Corporation | DNA encoding SNORF25 receptor |
BR0208051A (pt) * | 2001-03-07 | 2006-02-21 | Childrens Medical Center | método de seleção de bibliotecas de apresentação de peptìdeo que usa apresentação em minicélula |
US20030166099A1 (en) * | 2001-06-05 | 2003-09-04 | Sabbadini Roger A. | Minicells comprising membrane proteins |
-
2002
- 2002-05-28 EP EP02747872A patent/EP1487965A4/fr not_active Withdrawn
- 2002-05-28 CA CA002517027A patent/CA2517027A1/fr not_active Abandoned
- 2002-05-28 EP EP20110000796 patent/EP2390308A1/fr not_active Withdrawn
- 2002-05-28 AU AU2002318168A patent/AU2002318168B2/en not_active Expired
- 2002-05-28 EP EP10008869.9A patent/EP2272946B9/fr not_active Revoked
- 2002-05-28 ES ES10008869.9T patent/ES2541351T3/es not_active Expired - Lifetime
- 2002-05-28 WO PCT/US2002/016877 patent/WO2003072014A2/fr not_active Application Discontinuation
-
2011
- 2011-07-12 HK HK11107237.5A patent/HK1153229A1/xx not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003033519A2 (fr) * | 2001-10-15 | 2003-04-24 | Engeneic Gene Therapy Pty Limited | Mini-cellules entieres utilisees en tant que vecteurs pour le transfert d'adn et la therapie genique in vitro et in vivo |
Non-Patent Citations (3)
Title |
---|
GIACALONE ET AL: "Immune responses elicited by bacterial minicells capable of simultaneous DNA and protein antigen delivery", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 24, no. 33-34, 14 August 2006 (2006-08-14), pages 6009 - 6017, XP005571294, ISSN: 0264-410X * |
KHACHATOURIANS G G: "MINICELLS AS SPECIALIZED VACCINES AND VACCINE CARRIERS", ISAACSON, R. E. (ED.). RECOMBINANT DNA VACCINES: RATIONALE AND STRATEGY. XV+409P. MARCEL DEKKER, INC.: NEW YORK, NEW YORK, USA; BASEL, SWITZERLAND. ILLUS, 1992, pages 323 - 333, XP009072825, ISSN: 0-8247-8699-8 * |
SUZUKI M ET AL: "PRODUCTION IN ESCHERICHIA-COLI OF BIOLOGICALLY ACTIVE SECRETIN A GASTRO INTESTINAL HORMONE", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 79, no. 8, 1982, pages 2475 - 2479, XP002400466, ISSN: 0027-8424 * |
Also Published As
Publication number | Publication date |
---|---|
EP2272946B9 (fr) | 2015-06-24 |
EP2272946A2 (fr) | 2011-01-12 |
EP2272946A3 (fr) | 2011-07-27 |
CA2517027A1 (fr) | 2003-09-04 |
AU2002318168B2 (en) | 2007-12-13 |
ES2541351T3 (es) | 2015-07-17 |
WO2003072014B1 (fr) | 2004-04-22 |
WO2003072014A2 (fr) | 2003-09-04 |
AU2002318168A1 (en) | 2003-09-09 |
HK1153229A1 (en) | 2012-03-23 |
EP1487965A2 (fr) | 2004-12-22 |
WO2003072014A3 (fr) | 2004-02-12 |
EP2272946B1 (fr) | 2015-04-08 |
EP2390308A1 (fr) | 2011-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1153229A1 (en) | Minicell compositions and methods | |
GB0411940D0 (en) | Methods and compositions | |
EP1701725A4 (fr) | Methodes et compositions | |
AU2002357119A8 (en) | Mitocidal compositions and methods | |
EP1545481A4 (fr) | Compositions chimiotherapeutiques combinees et procedes correspondant | |
AU2003267644A8 (en) | Dental compositions and methods | |
AU2003256805A8 (en) | Compounds compositions and methods | |
HK1088837A1 (en) | Clk-peptide and slk-peptide | |
GB0208081D0 (en) | Skincare compositions and methods | |
AU2003275268A8 (en) | Hemostatic compositions and methods | |
AU2003297595A8 (en) | Atm kinase compositions and methods | |
GB0202059D0 (en) | Chemical compositions and methods | |
AU2003213120A8 (en) | Human rnase iii and compositions and uses thereof | |
AU2002357748A8 (en) | Osteopontin-related compositions and methods | |
GB2384705B (en) | Cosmetic and related compositions | |
AU2002366809A8 (en) | Syn3 compositions and methods | |
EP1583557A4 (fr) | Compositions vaccinales et procedes | |
AU2003302173A8 (en) | Spirotetrathiocarbamates and spirooxothiocarbamates | |
GB0207224D0 (en) | Tenascin-W compositions and uses thereof | |
GB0325942D0 (en) | Compositions and uses thereof | |
AU2002359869A8 (en) | Pak5-related compositions and methods | |
AU2003245524A8 (en) | Cryosurgery compositions and methods | |
GB0330062D0 (en) | Compositions and methods | |
GB0313059D0 (en) | Compositions and method | |
GB0220238D0 (en) | Novel use and compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20040922 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: MPEX PHARMACEUTICALS, INC. |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: BERKLEY, NEIL Inventor name: GIACALONE, MATTHEW Inventor name: SABBADINI, ROGER, A. Inventor name: SURBER, MARK |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20061013 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: VAXIION THERAPEUTICS INC |
|
17Q | First examination report despatched |
Effective date: 20090209 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: VAXIION THERAPEUTICS, LLC |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 35/66 20060101ALI20160714BHEP Ipc: C12N 1/00 20060101AFI20160714BHEP Ipc: A61K 48/00 20060101ALI20160714BHEP Ipc: A61K 9/48 20060101ALI20160714BHEP Ipc: C12N 15/70 20060101ALI20160714BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20160825 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTC | Intention to grant announced (deleted) | ||
INTG | Intention to grant announced |
Effective date: 20170206 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20170617 |